Vertex PharmaceuticalsActive
A first-in-class oral, non-opioid pain medicine (VX-548) that selectively inhibits the NaV1.8 sodium channel to block pain signals in the peripheral nervous system before they reach the brain - the first new class of pain drug in over 20 years.
Latest update Sep 8, 2026
01
FDA-approved January 30, 2025 for moderate-to-severe acute pain. Q2 2026 product revenue reached $50M. After the FDA declined a broad neuropathic-pain path, Vertex is running two Phase 3 diabetic-peripheral-neuropathy studies at 70mg once daily, with enrollment in both expected to complete by the end of 2026. Jasper van Grunsven took over the pain franchise on September 8, 2026.
02
03
Announced next steps from Vertex Pharmaceuticals that mention Journavx (suzetrigine).
End of 2026
TargetEnd of 2026 (DPN Phase 3 enrollment)
Broaden Journavx beyond acute pain into chronic pain. After the FDA indicated it did not see a path to a broad peripheral-neuropathic-pain label, Vertex narrowed its near-term plan to two identical, roughly 1,100-patient Phase 3 studies specifically in diabetic peripheral neuropathy (DPN) at a once-daily 70mg dose, with enrollment in both expected to complete by the end of 2026.
04
Vertex's flagship cystic fibrosis triple-combination CFTR modulator (elexacaftor/tezacaftor/ivacaftor), effective for roughly 90% of CF patients and the company's dominant revenue engine - now complemented by the once-daily next-generation Alyftrek.
The first approved CRISPR/Cas9 gene-editing medicine (exagamglogene autotemcel), a one-time therapy for sickle cell disease and transfusion-dependent beta thalassemia, developed and commercialized with CRISPR Therapeutics.
An allogeneic, stem-cell-derived, fully differentiated islet cell therapy for type 1 diabetes designed to restore the body's own insulin production - a potential functional cure delivered as a one-time infusion.
An oral, once-daily somatostatin receptor agonist for acromegaly, acquired through the Crinetics Pharmaceuticals deal - Vertex's first marketed product outside CF, pain, and gene therapy, and the anchor of its new endocrine-disease business.
05
Oklo
Oklo's fast-fission powerhouse product line is designed for build-own-operate deployment, targeting customers that want firm clean power in a smaller footprint than traditional large reactors.
Oklo
Oklo is developing an advanced fuel center to recycle used nuclear fuel and fabricate metal fuel for Aurora and other fast-reactor applications.
Oklo
Oklo's isotope business combines the Idaho Radiochemistry Laboratory, a planned pilot reactor in Texas, and a future multi-reactor foundry to supply critical medical, industrial, research, defense, and space isotopes.
TerraPower
Sodium-cooled fast reactor with integrated molten salt energy storage, enabling flexible output from 345 MWe to 500 MWe peak.